STOCK TITAN

DexCom (DXCM) insider Bridgette Heller files to sell 1,012 shares after grant

(Neutral)
(Neutral)
Form Type
144

Rhea-AI Filing Summary

DexCom, Inc. insider Bridgette P. Heller filed a notice of proposed sale of 1,012 shares of common stock of DXCM, to be sold through Fidelity Brokerage Services LLC on or after August 12, 2026 on NASDAQ. The shares were acquired via restricted stock vesting from the issuer as compensation on September 29, 2021. Heller also reported having sold 1,012 common shares during the past three months on May 12, 2026 for $60,730.12.

Positive

  • None.

Negative

  • None.
Proposed shares to be sold 1,012 shares Common stock sale through Fidelity on or after August 12, 2026
Aggregate market value of proposed sale $89,349.48 Value of 1,012 DexCom common shares planned for sale
Prior 3-month sale shares 1,012 shares Common stock sold on May 12, 2026
Proceeds from prior sale $60,730.12 Total proceeds from 1,012 shares sold on May 12, 2026
Acquisition date of shares September 29, 2021 Restricted stock vesting as compensation from issuer
Form 144 regulatory
"144: Securities To Be Sold"
Form 144 is a document that investors must file with the government when they plan to sell a large number of shares of a company's stock. It helps ensure transparency so everyone knows how many shares are being sold and when, which can impact the stock's price.
Restricted Stock Vesting financial
"Common | 09/29/2021 | Restricted Stock Vesting | Issuer"
Restricted stock vesting is the timetable and conditions under which shares granted to employees or insiders become fully owned and can be sold, typically requiring continued work or meeting performance goals. It matters to investors because large blocks of shares can become tradable at once, which can change share supply and price, and because vesting aligns insiders’ incentives with the company’s long‑term performance—think of it like a timed unlock that both rewards and locks in key people.
Compensation financial
"1012 | 09/29/2021 | Compensation"
Securities Sold During The Past 3 Months regulatory
"144: Securities Sold During The Past 3 Months"

FAQ

What does DexCom (DXCM) Form 144 filed by Bridgette P. Heller disclose?

The Form 144 discloses that Bridgette P. Heller intends to sell 1,012 shares of DexCom common stock through Fidelity on or after August 12, 2026, and that these shares came from restricted stock vesting awarded as compensation.

How many DexCom (DXCM) shares are proposed to be sold in this Form 144?

The filing reports a proposed sale of 1,012 shares of DexCom common stock. These shares are to be sold through Fidelity Brokerage Services LLC and are listed for trading on NASDAQ starting on or after August 12, 2026.

What is the aggregate market value of the DexCom (DXCM) shares in the proposed Form 144 sale?

The proposed sale covers shares with an aggregate market value of $89,349.48. This value is associated with the 1,012 DexCom common shares Heller plans to sell through Fidelity Brokerage Services LLC on or after August 12, 2026.

How and when did Bridgette P. Heller acquire the DexCom (DXCM) shares listed in the Form 144?

The filing states the shares were acquired via Restricted Stock Vesting from the issuer as compensation on September 29, 2021. This indicates the 1,012 common shares originated from an equity compensation award rather than an open-market purchase.

What DexCom (DXCM) stock sales has Bridgette P. Heller made in the past three months?

The Form 144 notes that Heller sold 1,012 shares of DexCom common stock on May 12, 2026 for total proceeds of $60,730.12. This prior transaction is listed in the section covering securities sold during the past 3 months.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
Learn about SEC filing dates

144: Filer Information

144: Issuer Information

144: Securities Information



Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold


* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.



Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

144: Remarks and Signature